Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center, collaborates with researchers from the Kenya Medical Research Institute ...

Human rights, key and vulnerable populations Ethiopia received PEPFAR funding for work on stigma, discrimination and enabling legal environments. As a result of the USG stop-work order, all programmes ...

Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples ...

Health Cabinet Secretary Deborah Barasa has reaffirmed Kenya's dedication to providing uninterrupted care for individuals living with HIV, despite recent challenges stemming from a freeze in foreign ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.